Image
Clinical Issues™

Clinical Issues in Psoriasis

Debates and Discussions About Pustular Disease Subtypes

Meeting Slides

Clinical Practice Guidelines

Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP.

Fujita H, et al. J Dermatol. 2018;45(11):1235-1270.

Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation.

Robinson A, et al. J Am Acad Dermatol. 2012;67(2):279-288.

Patient Resources

National Psoriasis Foundation

The NPF website provides an overview of symptoms, triggers, types, and treatment.

Psoriasis and Psoriatic Arthritis Alliance

The PAPAA provides an overview of pustular psoriasis and its various forms as well as available treatment options.

Suggested Readings

Pustular psoriasis: pathophysiology and current treatment perspectives.

Benjegerdes KE, et al. Psoriasis (Auckl). 2016;6:131-144.

Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial.

Bissonnette R, et al. J Eur Acad Dermatol Venereol. 2014;28(10):1298-1305.

Generalized pustular psoriasis—a model disease for specific targeted immunotherapy, systematic review.

Boehner A, et al. Exp Dermatol. 2018;27(10):1067-1077.

Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia.

Choon SE, et al. Int J Dermatol. 2014;53(6):676-684.

Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis.

Hagforsen E, et al. Br J Dermatol. 2010;163(3):572-579.

Generalized pustular psoriasis: a review and update on treatment.

Hoegler KM, et al. J Eur Acad Dermatol Venereol. 2018;32(10):1645-1651.

Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis.

Marrakchi S, et al. N Engl J Med. 2011;365(7):620-628.

What do we know about palmoplantar pustulosis?

Misiak-Galazka M, et al. J Eur Acad Dermatol Venereol. 2017;31(1):38-44.

Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum.

Murakami M, et al. Exp Dermatol. 2011;20(10):845-847.

Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects.

Raposo I, Torres T. Am J Clin Dermatol. 2016;17(4):349-358.

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J).

Saeki H, et al. J Dermatol. 2017;44(4):355-362.

The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: a systematic review.

Sanchez IM, et al. Dermatol Ther (Heidelb). 2017;7(4):425-446.

Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.

Sano S, et al. J Dermatol. 2018;45(5):529-539.

The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants.

Sugiura K. J Dermatol Sci. 2014;74(3):187-192.

Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial.

Terui T, et al. JAMA Dermatol. 2018;154(3):309-316.

Clinical and genetic differences between pustular psoriasis subtypes.

Twelves S, et al. J Allergy Clin Immunol. 2018. [Epub ahead of print].

Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.

Yamasaki K, et al. Br J Dermatol. 2017;176(3):741-751.

Relevant Resources

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Clinical Updates in Rheumatoid Arthritis

New Strategies to Target Remission and Individualize Comprehensive Care

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care